Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 2
1980 1
1981 1
1982 1
1984 2
1986 6
1987 7
1988 6
1989 16
1990 5
1991 4
1992 8
1993 2
1994 12
1995 10
1996 6
1997 4
1998 9
1999 6
2000 3
2001 6
2002 4
2003 4
2005 4
2006 5
2007 5
2008 8
2009 3
2010 3
2011 3
2012 6
2013 3
2014 1
2015 1
2016 2
2017 2
2018 2
2019 1
2020 2
2021 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

170 results
Results by year
Filters applied: . Clear all
Page 1
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Among authors: compston da. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
The pathogenesis of demyelinating disease.
Scolding NJ, Zajicek JP, Wood N, Compston DA. Scolding NJ, et al. Among authors: compston da. Prog Neurobiol. 1994 Jun;43(2):143-73. doi: 10.1016/0301-0082(94)90011-6. Prog Neurobiol. 1994. PMID: 7972853 Review. No abstract available.
HLA-DRB1 and multiple sclerosis in Malta.
Dean G, Yeo TW, Goris A, Taylor CJ, Goodman RS, Elian M, Galea-Debono A, Aquilina A, Felice A, Vella M, Sawcer S, Compston DA. Dean G, et al. Among authors: compston da. Neurology. 2008 Jan 8;70(2):101-5. doi: 10.1212/01.wnl.0000284598.98525.d7. Epub 2007 Dec 5. Neurology. 2008. PMID: 18057318
Histocompatibility antigens and post-encephalitic Parkinsonism.
Lees AJ, Stern GM, Compston DA. Lees AJ, et al. Among authors: compston da. J Neurol Neurosurg Psychiatry. 1982 Nov;45(11):1060-1. doi: 10.1136/jnnp.45.11.1060. J Neurol Neurosurg Psychiatry. 1982. PMID: 7175530 Free PMC article.
Immune-mediated oligodendrocyte injury.
Compston DA, Scolding NJ. Compston DA, et al. Ann N Y Acad Sci. 1991;633:196-204. doi: 10.1111/j.1749-6632.1991.tb15610.x. Ann N Y Acad Sci. 1991. PMID: 1789547 Review. No abstract available.
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators. Coles AJ, et al. Among authors: compston das. Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23. Neurology. 2017. PMID: 28835403 Free PMC article.
170 results